Bispecific Antibodies for Cancer Market Size to Grow by USD 396.56 million, Emerging Bispecific Antibody Generation Platforms to be Key Trend - Technavio

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- In the bispecific antibodies for cancer market, emerging bispecific antibody generation platforms will be a key trend during the forecast period. For instance, Xencor is developing XmAb20717, XmAb22841, XmAb23104, XmAb24306, and XmAb14045, which are currently in the early phase of development, using the XmAb antibody engineering platform. In addition, Aptevo Therapeutics has developed APVO436 using its ADAPTIR platform for treating patients with acute myeloid leukemia. Therefore, such platforms will drive market growth during the forecast period.

The bispecific antibodies for cancer market size is expected to grow by USD 396.56 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 9.06% during the forecast period, according to Technavio. 

Our comprehensive report summary includes the market size and forecast along with
research methodology. The FREE sample report is available in PDF format

The increasing prevalence of cancer is driving the growth of the bispecific antibodies for cancer market growth. However, factors such as the high cost of drugs may challenge the market growth during the forecast period.

Bispecific Antibodies For Cancer Market: Type Landscape

By type, the market has been segmented into CD19 or CD3 and CD30 or CD16A. The CD19 or CD3 segment will be the largest contributor to market growth during the forecast period. Bispecific antibodies have several advantages when compared to monoclonal antibodies. They can redirect specific immune cells to the site of the tumor cells to boost tumor killing. In addition, they can potentially increase the binding specificity by interacting with two different cell-surface antigens instead of one. They are also able to block two different pathways that exert unique pathogenesis simultaneously. Such advantages will drive the growth of the segment during the forecast period.

Bispecific Antibodies For Cancer Market: Geographic Landscape

Based on geography, the market has been segmented into North America, Europe, Asia, and Rest of World (ROW). North America is expected to have significant growth during the forecast period. About 39% of the market's overall growth is expected to originate from this region. The US is the key country for the bispecific antibodies for the cancer market in North America. The growth of this region is attributed to factors such as the availability of reimbursement schemes. Moreover, this region is expected to grow at a faster rate than other regions.

Find out about the contribution of each region of the market. Buy Now to gain access to
country-specific information

Companies Covered

• ABL Bio Inc.
• AFFIMED N.V.
• Akeso Inc.
• Amgen Inc.
• Aptevo Therapeutics Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Eli Lilly and Co.
• EPIMAB BIOTHERAPEUTICS INC.
• F. Hoffmann La Roche Ltd.
• F-STAR THERAPEUTICS INC.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson Inc.
• Mereo BioPharma Group Plc
• Merus N.V.
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• TG Therapeutics Inc.
• Xencor Inc.
• Y mAbs Therapeutics Inc.

For learning about strategic initiatives used by vendors, as well as key news and the
latest developments, View our FREE PDF Sample Report Now

What our reports offer

• Market share assessments for regional-level and country-level segments
• Strategic recommendations for the new entrants
• Covers market data for 2021, 2022, until 2026
• Market trends (opportunities, drivers, threats, challenges, investment opportunities, and recommendations)
• Strategic recommendations in key business segments as per the market approximations
• Competitive landscaping highlighting the common trends
• Company profiling with detailed strategies, recent developments, and financials
• Supply chain trends that map the latest technological advances

Related Reports

Non-melanoma Skin Cancer Market by Type and Geography - Forecast and Analysis 2022-2026: The non-melanoma skin cancer market share is expected to increase by USD 180.97 million from 2021 to 2026.

Colorectal Cancer Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026: The colorectal cancer therapeutics market share is expected to increase by USD 2.45 bn from 2021 to 2026.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type 
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 CD19 or CD3 - Market size and forecast 2021-2026
• Exhibit 28: Chart on CD19 or CD3 - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on CD19 or CD3 - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on CD19 or CD3 - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on CD19 or CD3 - Year-over-year growth 2021-2026 (%)

• 5.4 CD30 or CD16A - Market size and forecast 2021-2026
• Exhibit 32: Chart on CD30 or CD16A - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on CD30 or CD16A - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on CD30 or CD16A - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on CD30 or CD16A - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Ireland - Market size and forecast 2021-2026
• Exhibit 62: Chart on Ireland - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Ireland - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Ireland - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Ireland - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Hungary - Market size and forecast 2021-2026
• Exhibit 70: Chart on Hungary - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Hungary - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Hungary - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Hungary - Year-over-year growth 2021-2026 (%)

• 7.11 India - Market size and forecast 2021-2026
• Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 ABL Bio Inc. 
• Exhibit 85: ABL Bio Inc. - Overview
• Exhibit 86: ABL Bio Inc. - Product / Service
• Exhibit 87: ABL Bio Inc. - Key offerings

• 10.4 Amgen Inc. 
• Exhibit 88: Amgen Inc. - Overview
• Exhibit 89: Amgen Inc. - Product / Service
• Exhibit 90: Amgen Inc. - Key offerings

• 10.5 Astellas Pharma Inc. 
• Exhibit 91: Astellas Pharma Inc. - Overview
• Exhibit 92: Astellas Pharma Inc. - Product / Service
• Exhibit 93: Astellas Pharma Inc. - Key news
• Exhibit 94: Astellas Pharma Inc. - Key offerings

• 10.6 Eli Lilly and Co. 
• Exhibit 95: Eli Lilly and Co. - Overview
• Exhibit 96: Eli Lilly and Co. - Business segments
• Exhibit 97: Eli Lilly and Co. - Key offerings
• Exhibit 98: Eli Lilly and Co. - Segment focus

• 10.7 F. Hoffmann La Roche Ltd. 
• Exhibit 99: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 100: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 101: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 102: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 103: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Johnson and Johnson Inc. 
• Exhibit 104: Johnson and Johnson Inc. - Overview
• Exhibit 105: Johnson and Johnson Inc. - Business segments
• Exhibit 106: Johnson and Johnson Inc. - Key news
• Exhibit 107: Johnson and Johnson Inc. - Key offerings
• Exhibit 108: Johnson and Johnson Inc. - Segment focus

• 10.9 Merus N.V. 
• Exhibit 109: Merus N.V. - Overview
• Exhibit 110: Merus N.V. - Key offerings

• 10.10 Pfizer Inc. 
• Exhibit 111: Pfizer Inc. - Overview
• Exhibit 112: Pfizer Inc. - Product / Service
• Exhibit 113: Pfizer Inc. - Key news
• Exhibit 114: Pfizer Inc. - Key offerings

• 10.11 Regeneron Pharmaceuticals Inc. 
• Exhibit 115: Regeneron Pharmaceuticals Inc. - Overview
• Exhibit 116: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibit 117: Regeneron Pharmaceuticals Inc. - Key offerings

• 10.12 TG Therapeutics Inc. 
• Exhibit 118: TG Therapeutics Inc. - Overview
• Exhibit 119: TG Therapeutics Inc. - Product / Service
• Exhibit 120: TG Therapeutics Inc. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 121: Inclusions checklist
• Exhibit 122: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 123: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 124: Research methodology
• Exhibit 125: Validation techniques employed for market sizing
• Exhibit 126: Information sources

• 11.5 List of abbreviations 
• Exhibit 127: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED